TOP-N53
Phase 2Small molecule
TOP-N53 is one of 36 small molecule programs targeting Systemic Sclerosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
165 competitors in Systemic Sclerosis
#DrugCompanyPhaseTrials
1Actemra
RochePhase 3
Fludara
SanofiPhase 3
Medrol
PfizerPhase 3
Opsumit
Johnson & JohnsonPhase 3
Rinvoq
AbbViePhase 3
Cysteine Hydrochloride
NovartisPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Ofev
Boehringer IngelheimPhase 3
Esbriet
LLegacy Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TOP-N53. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTopadur Pharma AG